Docetaxel/Prednisone Versus Docetaxel/Prednisone and Enzalutamide in Castration-Resistant Prostate Cancer (Doce/Enza)

A Phase II Randomized Prospective Trial of Docetaxel/Prednisone Versus Docetaxel/Prednisone and Enzalutamide in Castration-Resistant Prostate Cancer (CRPC) Patients Progressing on Enzalutamide

This is a prospective randomized phase II clinical trial where patients who are receiving enzalutamide in the pre-chemotherapy space are randomized upon objective progression (radiographic and/or clinical per PCWG2 criteria) to docetaxel/prednisone alone or the same combination plus enzalutamide.

The primary aim is to evaluate whether continuing enzalutamide in combination with docetaxel in patients who failed or progressed while on enzalutamide would increase progression-free survival (PFS) by 4 months. The secondary end points are PSA responses, percent of patients alive at 1 and 2 years, decline in circulating tumor cells (CTCs), and quality of life (QOL) using validated scales.

Study Overview

• Status: Terminated
• Conditions: Prostate Cancer
• Intervention / Treatment: Drug: Docetaxel; Drug: Prednisone; Drug: Enzalutamide

• Study Type: Interventional
• Enrollment (Actual): 9
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • Illinois
    • Chicago, Illinois, United States, 60637
      • The University of Chicago
    • Decatur, Illinois, United States, 62526
      • Decatur Memorial Hospital
    • Evanston, Illinois, United States, 60201
      • NorthShore University HealthSytem - Kellogg Cancer Center
  • New York
    • Buffalo, New York, United States, 14263
      • Roswell Park Cancer Institute
  • Wisconsin
    • Madison, Wisconsin, United States, 53705
      • Univesity of Wisconsin

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Male

Description

Inclusion Criteria:

• Willing and able to provide written informed consent and HIPAA authorization for the release of personal health information.

NOTE: HIPAA authorization may be either included in the informed consent or obtained separately.

• Males 18 years of age and above
• Histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features
• Having documented disease progression on enzalutamide defined by 1 or more of the following criteria:
• PSA progression according to PCWG2 criteria with 3 consecutive rising PSA measurements, all collected at least 1 week apart
• Radiographic progression in soft tissue or bone by modified RECIST 1.1 for subjects with measurable disease; or
• Bone disease progression defined by 2 or more new lesions on 2 consecutive bone scans in the absence of falling PSA
• Patients who have not had a bilateral orchiectomy must have a plan to maintain effective GnRG-analogue therapy for the duration of the trial
• Serum testosterone level < 50 ng/dL at Screening visit
• ECOG PS: 0-1
• Throughout the study, male patients and their female partners of childbearing potential must use 2 acceptable methods of birth control (1 of which must include a condom as a barrier method of contraception) starting at screening and continuing throughout the study period and for 3 months after final study drug administration. Two acceptable methods of birth control thus include the following:
• Condom (barrier method of contraception even if having sex with a pregnant woman)

• One of the following is required:

  • Established use of oral, injected, or implanted hormonal method of contraception by the female partner
  • Placement of an intrauterine device (IUD) or intrauterine system (IUS) by the female partner
  • Additional barrier method: Occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository by the female partner
  • Tubal litigation in the female partner
  • Vasectomy or other procedure resulting in infertility (eg, bilateral orchiectomy) for >6 months
• Patients must have adequate organ and marrow function as defined below
• Leukocytes >3,000/mm3
• absolute neutrophil count >1,500/mm3
• platelets >100,000/mm3
• total bilirubin within normal institutional limits (or <2X the upper limit of normal in those with Gilbert's disease)
• AST(SGOT)/ALT(SGPT) <1.5 X institutional upper limit of normal
• creatinine within normal institutional limits OR
• creatinine clearance* >45 mL/min/1.73 m2 for patients with creatinine levels above institutional normal
• Estimated life expectancy of > 6 months
• Able to swallow the study drug as prescribed and comply with study requirements

Exclusion Criteria:

• Prior treatment with docetaxel-based chemotherapy
• Prior treatment with abiraterone acetate
• Prior treatment with cabazitaxel
• Severe concurrent disease, infection, or co-morbidity that, in the judgment of the Investigator, would make the patient inappropriate for enrollment
• Ongoing investigational treatment
• Medical conditions such as uncontrolled hypertension, uncontrolled diabetes mellitus, cardiac disease that would, in the opinion of the investigator, make this protocol unreasonably hazardous
• Major surgery within 4 weeks of enrollment
• Use of an investigational therapeutic agent with 4 weeks of enrollment
• History of seizure or any condition that may predispose to seizure.
• History of loss of consciousness or transient ischemic attack within 12 months of enrollment
• Gastrointestinal disorder affecting absorption (e.g., gastrectomy, active peptic ulcer disease) within last 3 months
• Grade > 2 treatment-related toxicity from prior therapy
• History of hypersensitivity to polysorbate 80
• Any known allergy to the compounds under investigation
• Any other condition which, in the opinion of the Investigator, would preclude participation in this trial

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Docetaxel/Prednisone; Docetaxel 75 mg/m2 day 1 (every 21-days) plus prednisone 5 mg po bid throughout	Drug: Docetaxel; Drug: Prednisone
Active Comparator: Docetaxel/Prednisone + Enzalutamide; Docetaxel 75 mg/m2 day 1 (every 21-days) plus prednisone 5 mg po bid throughout plus Enzalutamide 160 mg daily throughout. Subjects will continue enzalutamide until PD after 10 cycles of docetaxel.	Drug: Docetaxel; Drug: Prednisone; Drug: Enzalutamide

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Progression-free Survival (Radiographic or Per PCWG2 Criteria)	The primary endpoint of the study is progression-free survival (PFS), defined as the time from randomization to disease progression. Progression will be evaluated using a combination of RECIST and Prostate Cancer Working Group 2 guidelines.	1 year

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
PSA Response in the Standard Treatment Arm and Experimental Treatment Arm	PSA response measured according to Prostate Cancer Working Group 2 (PCWG2). The study was terminated after only 9 patients enrolled, 5 to the standard of care docetaxel/prednisone arm and 4 to experimental docetaxel/prednisone/enzalutamide arm.	Baseline, Day 84 (C4D1), Day 147 (C7D1), Day 210 (C10D1), Day 231, and every 21 days through study completion (an average of 1 year)
Overall Survival		At both 1 year and 2 years from treatment start

Other Outcome Measures

Outcome Measure	Time Frame
Quality of Life (QOL)	Baseline, Day 84 (C4D1), Day 147 (C7D1), Day 210 (C10D1), Day 231 and every 21 days through study completion (an average of 1 year)
Circulating Tumor Cells (CTCs)	Baseline, Day 84 (C4D1), Day 147 (C7D1), Day 210 (C10D1), and every 63 days through study completion (an average of 1 year)
Analysis of Androgen Receptor Splice Variant	Baseline, Day 84 (C4D1), Day 147 (C7D1), Day 210 (C10D1), and every 63 days through study completion (an average of 1 year)

Collaborators and Investigators

• Sponsor: Prostate Cancer Clinical Trials Consortium
• Collaborators: University of Chicago; Astellas Pharma Inc

Study record dates

Study Major Dates

• Study Start: February 1, 2016
• Primary Completion (Actual): August 1, 2017
• Study Completion (Actual): August 1, 2017

Study Registration Dates

• First Submitted: February 9, 2016
• First Submitted That Met QC Criteria: February 12, 2016
• First Posted (Estimate): February 18, 2016

Study Record Updates

• Last Update Posted (Actual): April 9, 2021
• Last Update Submitted That Met QC Criteria: March 11, 2021
• Last Verified: March 1, 2021

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Genital Neoplasms, Male; Prostatic Diseases; Prostatic Neoplasms; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Anti-Inflammatory Agents; Antineoplastic Agents; Tubulin Modulators; Antimitotic Agents; Mitosis Modulators; Glucocorticoids; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Antineoplastic Agents, Hormonal; Docetaxel; Prednisone
• Other Study ID Numbers: c13-126